Clinical Trial

Low-Dose Radiation + SBRT + Tislelizumab Plus Platinum-based Chemotherapy in Stage ⅡA-ⅢB Non-small Cell Lung Cancer

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This phase II study aims to evaluate the efficacy and safety of low-dose radiation + SBRT + Tislelizumab plus platinum-based chemotherapy as neoadjuvant therapy for stage II-III non-small cell lung cancer.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-10; most recent amendment 2025-12-29.
Status change: Not Yet Recruiting → Recruiting 2025-12-29
Trial Details
NCT Number NCT06877299
Lead Sponsor Sichuan University
Conditions Lung Cancer, Non-small Cell Lung Cancer
Enrollment 30 participants
Start Date 2025-07-04
Primary Completion 2027-06-30 (estimated)
Study Completion 2028-01-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-02